| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
310,240,000 |
| Market
Cap: |
11.76(B) |
| Last
Volume: |
3,474,576 |
Avg
Vol: |
2,436,524 |
| 52
Week Range: |
$32.38 - $46.26 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Research Services |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
735,409 |
| Total Buy Value |
$0 |
$0 |
$0 |
$15,268,727 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
4 |
| Total Shares Sold |
0 |
456,605 |
970,613 |
1,894,029 |
| Total Sell Value |
$0 |
$20,966,384 |
$39,541,372 |
$62,800,429 |
| Total People Sold |
0 |
9 |
14 |
16 |
| Total Sell Transactions |
0 |
11 |
28 |
54 |
| End Date |
2025-08-07 |
2025-05-06 |
2024-11-05 |
2023-11-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Aftab Dana |
EVP, Research & Development |
• – – |
2025-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
50,673 |
713,161 |
|
- |
|
| Wyszomierski Jack L |
Director |
– • – |
2025-06-03 |
4 |
AS |
$43.09 |
$324,683 |
D/D |
(7,535) |
358,882 |
|
-11% |
|
| Eckhardt Sue Gail |
Director |
– • – |
2025-06-02 |
4 |
AS |
$42.74 |
$805,140 |
D/D |
(18,838) |
21,380 |
|
-10% |
|
| Smith Julie |
Director |
– • – |
2025-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
9,812 |
20,590 |
|
- |
|
| Beckerle Mary C |
Director |
– • – |
2025-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
9,812 |
40,218 |
|
- |
|
| Heyman Tomas J. |
Director |
– • – |
2025-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
9,812 |
42,282 |
|
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2025-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
9,812 |
1,289,228 |
|
- |
|
| Eckhardt Sue Gail |
Director |
– • – |
2025-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
9,812 |
40,218 |
|
- |
|
| Freire Maria C |
Director |
– • – |
2025-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
9,812 |
100,819 |
|
- |
|
| Poste George |
Director |
– • – |
2025-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
9,812 |
178,832 |
|
- |
|
| Wyszomierski Jack L |
Director |
– • – |
2025-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
9,812 |
366,417 |
|
- |
|
| Oliver Bob |
Director |
– • – |
2025-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
9,812 |
43,326 |
|
- |
|
| Heyman Tomas J. |
Director |
– • – |
2025-05-21 |
4 |
S |
$44.29 |
$201,254 |
D/D |
(4,544) |
32,470 |
|
6% |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2025-05-20 |
4 |
S |
$44.06 |
$1,515,091 |
D/D |
(34,387) |
412,072 |
|
9% |
|
| Peterson Amy C. |
EVP Prod Dev & Med Aff & CMO |
• – – |
2025-05-16 |
4 |
S |
$45.47 |
$3,309,125 |
D/D |
(72,776) |
465,393 |
|
15% |
|
| Peterson Amy C. |
EVP Prod Dev & Med Aff & CMO |
• – – |
2025-05-16 |
4 |
OE |
$21.75 |
$870,000 |
D/D |
40,000 |
538,169 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2025-05-16 |
4 |
GA |
$0.00 |
$0 |
I/I |
87,871 |
1,852,856 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2025-05-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
87,871 |
1,518,240 |
|
- |
|
| Poste George |
Director |
– • – |
2025-05-16 |
4 |
S |
$45.99 |
$948,958 |
D/D |
(20,634) |
169,020 |
|
15% |
|
| Poste George |
Director |
– • – |
2025-05-16 |
4 |
OE |
$19.77 |
$407,934 |
D/D |
20,634 |
189,654 |
|
- |
|
| Senner Christopher J. |
EVP and CFO |
• – – |
2025-05-16 |
4 |
S |
$46.00 |
$4,600,000 |
D/D |
(100,000) |
967,842 |
|
15% |
|
| Senner Christopher J. |
EVP and CFO |
• – – |
2025-05-16 |
4 |
OE |
$18.80 |
$1,880,000 |
D/D |
100,000 |
1,067,842 |
|
- |
|
| Peterson Amy C. |
EVP Prod Dev & Med Aff & CMO |
• – – |
2025-05-15 |
4 |
D |
$44.65 |
$370,729 |
D/D |
(8,303) |
498,169 |
|
- |
|
| Aftab Dana |
CSO/EVP Disc & Trans Research |
• – – |
2025-05-15 |
4 |
D |
$44.65 |
$1,370,442 |
D/D |
(30,693) |
662,488 |
|
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2025-05-15 |
4 |
S |
$44.35 |
$1,619,130 |
D/D |
(36,508) |
1,279,416 |
|
16% |
|
1112 Records found
|
|
Page 1 of 45 |
|
|
0.16 (0.42%) 
